Venture Capital

Chinese Human Vaccine-focused Biotech Firm Gets $36M In Series A Round – China Money Network

by chinamoneynetwork.com posted 1year ago 99 views
Chinese biotechnology firm Zhongyianke Biotech announced on Thursday that it has raised RMB250 million (US$36.35 million) in a series A round of financing from a group of investors including Chinese investment firm Shenzhen Qianhai Beizeng Asset Management.